KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cash from Investing Activities (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Cash from Investing Activities for 9 consecutive years, with -$83.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 569.11% year-over-year to -$83.5 million, compared with a TTM value of -$13.7 million through Dec 2025, down 126.04%, and an annual FY2025 reading of -$13.7 million, down 126.04% over the prior year.
  • Cash from Investing Activities was -$83.5 million for Q4 2025 at Biocryst Pharmaceuticals, down from $13.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $29.1 million in Q2 2025 and bottomed at -$107.1 million in Q1 2023.
  • Average Cash from Investing Activities over 3 years is -$7.7 million, with a median of $11.0 million recorded in 2024.
  • Peak annual rise in Cash from Investing Activities hit 1289.34% in 2025, while the deepest fall reached 569.11% in 2025.
  • Year by year, Cash from Investing Activities stood at -$28.5 million in 2023, then soared by 162.5% to $17.8 million in 2024, then tumbled by 569.11% to -$83.5 million in 2025.
  • Business Quant data shows Cash from Investing Activities for BCRX at -$83.5 million in Q4 2025, $13.6 million in Q3 2025, and $29.1 million in Q2 2025.